Effect of Cytochrome P450 and ABCB1 Polymorphisms on Imatinib Pharmacokinetics After Single-Dose Administration to Healthy Subjects.

Abstract

Validated genomic biomarkers for oncological drugs are expanding to improve targeted therapies. Pharmacogenetics research focusing on the mechanisms underlying imatinib suboptimal response might help to explain the different treatment outcomes and drug safety profiles. To investigate whether polymorphisms in genes encoding cytochrome P450 (CYP)enzymes and ABCB1 transporter affect imatinib pharmacokinetic parameters. A prospective, multicenter, pharmacogenetic pilot study was performed in the context of two separate oral imatinib bioequivalence clinical trials, which included 26 healthy volunteers. DNA was extracted in order to analyze polymorphisms in genes CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and ABCB1. Imatinib plasma concentrations were measured by HPLC-MS/MS. Pharmacokinetic parameters were calculated by non-compartmental methods using WinNonlin software. Volunteers (n = 26; aged 24 ± 3years; 69% male) presented regular pharmacokinetic imatinib data (concentration at 24h, 436 ± 140ng/mL and at 72h, 40 ± 26ng/mL; AUC0-72 32,868 ± 10,713ng/mL⋅h; and Cmax 2074 ± 604ng/mL). CYP2B6 516GT carriers showed a significant reduction of imatinib concentration at 24h (23%, 391ng/dL vs 511ng/dL in 516GG carriers, p = 0.005) and elimination half-life (11%, 12.6h vs 14.1h in 516GG carriers, p = 0.041). Carriers for CYP3A4 (*22/*22, *1/*20 and *1/*22 variants) showed a reduced frequency of adverse events compared to *1/*1 carriers (0 vs 64%, p = 0.033). The other polymorphisms analyzed did not influence pharmacokinetics or drug toxicity. CYP2B6 G516T and CYP3A4 *20,*22 polymorphisms could influence imatinib plasma concentrations and safety profile, after single-dose administration to healthy subjects. This finding needs to be confirmed before it is implemented in clinical practice in oncological patients under treatment with imatinib.